Relation between structure and function in azoles;Relación entre estructura y función en los azoles

Revista Espanola de Quimioterapia

Volumn 17, Issue 1, 2004, Pages 71-78

  Sadaba B ^a   Garcia Quetglas E ^a   Azanza, J R ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MIDAZOLAM; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIMOZIDE; POSACONAZOLE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABDOMINAL BLEEDING; ANOREXIA; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; INHIBITION KINETICS; MEDICAL LITERATURE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PHOTOPHOBIA; PHOTOSENSITIVITY; SKIN MANIFESTATION; SPAIN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTIFUNGAL AGENTS; AZOLES; HUMANS; MYCOSES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2542449112     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Steinbach, W.J., Stevens, D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37 (Suppl. 3): S157-S187.
2. Balkis, M.M., Leidich, S.D., Mukherjee, P.K., Ghannoum, M.A. Mechanisms of fungal resistance: An overview. Drugs 2002; 62: 1025-1040.
3. Walsh, T.J., Viviani, M.A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A.H. Odds new targets and delivery systems for antifungal therapy. Med Mycol 2000; 38 (Suppl. 1): 335-347.
4. Chandrasekar, P.H., Manavathu, E. Voriconazole: A second generation triazole. Drugs of Today 2001; 37: 135-148.
5. Yoshida, Y., Aoyama, Y. Stereoselective interaction of an azole antifungal agent with its target, lanosterol 14 alpha-demethylase (cytochrome P-45014DM): A model study with stereoisomers of triadimenol and purified cytochrome P-45014DM from yeast. Chirality 1990; 2: 10-15.
6. Ji, H., Zhang, W., Zhou, Y., Zhang, M., Zhu, J., Song, Y., Lu, J. A three-dimensional model of lanosterol 14 alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000; 43: 2493-2505.
7. Fukuoka, T., Johnston, D.A., Winslow, C.A. y cols. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003; 47: 1213-1219.
8. Purkins, L., Kleinermans, D., Greenhalgh, K. y cols. The effect of food on voriconazole pharmacokinetics. En: 4th Trends in Invasive Fungal Infections, Barcelona, Spain 1997; Abst. P-88.
9. Barone, J.A., Koh, J.G., Bierman, R.H. y cols. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-784.
10. Van Peer, A., Woestenborghs, R., Heykants, J., Gasparini, R., Gauwenbergh, G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36: 423-426.
11. Walsh, T.J., Pappas, P., Winston, D.J. y cols. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
12. Schwartz, S., Milatovic, D., Thiel, E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-665.
13. Herbrecht, R., Denning, D.W., Patterson, T.F. y cols. Voriconazole versus amphotericin B for primary therapy of invasive aspergillossis. N Engl J Med 2002; 347: 408-415.
14. Dening, D.W., del Favero, A., Gluckman, E. y cols. The efficacy and tolerability of UK 109-496 (voriconazole) in the treatment of invasive aspergillosis (IA). En: 13th Congress of the International Society for Human and Animal Mycology (ISHAM), Parma, Italy 1997.
15. Dening, D.W., Ribaud, P., Milpied, N. y cols. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
16. Mouas, H., Lortholary, O., Alexandre, M. y cols. Aspergillus fumigatus spondylodiscitis successfully treated by voriconazole in a non-immunocompromised patient. En: 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, USA 2001.
17. Torre Cisneros, J., González-Ruiz, A., Hodges, M.R., Lutsar, I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. En: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, USA 2000.
18. Muñoz, P., Marín, M., Tornero, P., Martín Rabadán, P., Rodríguez-Creixéms, M., Bouza, E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31: 1499-1501.
19. Nesky, M.A., McDougal, C.C., Peacock, J. Pseudoallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and review of CNS pseudoallescheriasis. En: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, USA 2000.
20. Perfect, J., Lutsar, I., González-Ruiz, A. Voriconazole (VOR1) for the treatment of resistant and rare fungal pathogens. En: 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, USA 2000.
21. Walsh, T.J., Lutsar, I., Ghahramani, P., Hodges, M.R. Efficacy and safety of voriconazole (VORI) in the treatment of invasive fungal infection in children. En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada 2000; Abst. A-1110.
22. Werweij, P.E., And Den Bergh, M.F., Rath, P.M., De Pauw, B.E., Voss, A.M. Invasive aspergillosis caused by Aspergillus ustus. Case report and review. J Clin Microbiol 1999; 37: 1606-1609.
23. Hoepelman, A.I.M., Hodges, M.R., Lutsar, I. Cerebral aspergillosis and scedosporinosis: Voriconazole. A new treatment option for children with life-threattening cerebralfungal infection. En: 18th Europ Soc Paedriatric Infectious Dis, Noordwijk 2000.
24. Tan, K.K.C., Wood, N., Weil, A. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment. En: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA 2001; Abst. A-16.
25. Poirier, I.M., Cheymol, G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-73.
26. Tomaszewski, K., Purkins, L. The pharmacokinetics (PK) and safety of sulphobutylether-b-cyclodextrin (SBECD). En: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA 2001; Abst. A-23.